Questions about COVID-19?

What Patients & Families Need to Know | New Visitor PolicyGuidance for Community Healthcare Providers

A photo of James Mulloy.

Co-Leader, Hematological Malignancy Program

Professor, UC Department of Pediatrics

513-636-1844

513-636-3768

Biography & Affiliation

Academic Affiliation

Professor, UC Department of Pediatrics

Departments

Experimental Hematology and Cancer Biology, Cancer and Blood Diseases

Education

BA: St. Anselm College, Manchester, NH, 1986.

MS: Rutgers University-University of Medicine and Dentistry, New Brunswick, NJ, 1989.

PhD: Rutgers University-University of Medicine and Dentistry, New Brunswick, NJ, 1992.

Publications

Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Melgar, K; Walker, MM; Jones, LM; Bolanos, LC; Hueneman, K; Wunderlich, M; Jiang, J; Wilson, KM; Zhang, X; Sutter, P; et al. Science Translational Medicine. 2019; 11:eaaw8828-eaaw8828.

Epigenetic Regulator Genes Direct the Fate of Multipotent Progenitor Cell of Origin in Lineage Switched MLL-AF4 Leukaemia. Tirtakusuma, R; Milne, P; Ptasinska, A; Meyer, C; Nakjang, S; Komkov, A; Williamson, D; Cauchy, P; Assi, S; Blair, H; et al. 2019.

Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. Huang, Y; Su, R; Sheng, Y; Dong, L; Dong, Z; Xu, H; Ni, T; Zhang, ZS; Zhang, T; Li, C; et al. Cancer Cell. 2019; 35:677-691.e10.

Alternative translation initiation generates the N-terminal truncated form of RUNX1 that retains hematopoietic activity. Goyama, S; Schibler, J; Mulloy, JC. Experimental Hematology. 2019; 72:27-35.

Improved chemotherapy modeling with RAG-based immune deficient mice. Wunderlich, M; Manning, N; Sexton, C; Sabulski, A; Byerly, L; O’Brien, E; Perentesis, JP; Mizukawa, B; Mulloy, JC. PLoS ONE. 2019; 14:e0225532-e0225532.

Improved multilineage human hematopoietic reconstitution and function in NSGS mice. Wunderlich, M; Chou, F; Sexton, C; Presicce, P; Chougnet, CA; Aliberti, J; Mulloy, JC. PLoS ONE. 2018; 13:e0209034-e0209034.

Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response. Barve, A; Casson, L; Krem, M; Wunderlich, M; Mulloy, JC; Beverly, LJ. Experimental Hematology. 2018; 67:18-31.

METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m(6)A Modification. Weng, H; Huang, H; Wu, H; Qin, X; Zhao, BS; Dong, L; Shi, H; Skibbe, J; Shen, C; Hu, C; et al. Cell Stem Cell. 2018; 22:191-205.e9.

R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m(6)A/MYC/CEBPA Signaling. Su, R; Dong, L; Li, C; Nachtergaele, S; Wunderlich, M; Qing, Y; Deng, X; Wang, Y; Weng, X; Hu, C; et al. Cell. 2018; 172:90-105.e23.

Cell polarity and division symmetry analyses in transformed blood cells. Mizukawa, B; O’Brien, E; Mulloy, JC; Zheng, Y. Methods in molecular biology (Clifton, N.J.). 2018; 1821:257-266.